How many insider trades does FilingIQ track for VBIO?

FilingIQ tracks 30 Form 4 insider transactions for VBIO (Valion Bio, Inc.), covering filings from Jul 15, 2016 onwards. 2 of those were filed in the last 90 days.

Are VBIO insiders net buyers or net sellers?

Across the full Form 4 history for VBIO, 17 transactions (57%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does VBIO insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is VBIO in?

Valion Bio, Inc. (VBIO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $507698.

VBIO insider trading

NasdaqCM Healthcare

Valion Bio, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

57% / 0%

Market cap

$507698

About Valion Bio, Inc.

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

Company website: valionbio.com

VBIO insider activity at a glance

FilingIQ has scored 30 insider transactions for VBIO since Jul 15, 2016. The most recent filing in our index is dated Jun 18, 2026.

Across the full history, 17 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on VBIO insider trades is 51.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live VBIO trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 983

UNITED THERAPEUTICS Corp

NUVL 195

Nuvalent, Inc.

KYMR 193

Kymera Therapeutics, Inc.

GH 192

Guardant Health, Inc.

Hims & Hers Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for VBIO?: FilingIQ tracks 30 Form 4 insider transactions for VBIO (Valion Bio, Inc.), covering filings from Jul 15, 2016 onwards. 2 of those were filed in the last 90 days.
Are VBIO insiders net buyers or net sellers?: Across the full Form 4 history for VBIO, 17 transactions (57%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does VBIO insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is VBIO in?: Valion Bio, Inc. (VBIO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $507698.

Methodology & sources

Every VBIO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.